Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...
CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...
argenx’s Vygart Hytrulo Approved in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Holland-based argenx SE (NASDAQ: ARGX) has announced receiving another indication approval from Japan’s Ministry of...
Daiichi Sankyo’s Datroway Approved in Japan for HR+, HER2- Breast Cancer
Japan-based pharmaceutical company Daiichi Sankyo (TYO: 4568) has announced that it has received marketing approval...
MabPharm’s CMAB807 Biosimilar Receives Market Approval in Indonesia and Peru
Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the...
Shanghai Ark Biopharmaceutical Partners with Partex to Advance AI-Driven Drug Development
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has formed a strategic alliance with Germany-based Partex, an...
Zhongheng Group and Fosun Pharmaceutical Form JV to Boost Overseas Business
China-based Zhongheng Group (SHA: 600252) has announced plans to establish a joint venture (JV) with...
BeiGene’s Tevimbra Receives FDA Approval for HER2-Negative Gastric Cancer Treatment
China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that the...
Huadong Medicine Partners with SynerK PharmaTech for Hypertension siRNA Drug Development
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a strategic partnership agreement with SynerK...
NMPA Releases 87th Batch of Reference Drugs for Generic Quality Consistency
The National Medical Products Administration (NMPA) has released the 87th batch of reference drugs for...
Bristol-Myers Squibb’s Opdivo Qvantig Receives FDA Approval for Expanded Indications
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that the US Food and...
HitGen Inc. Initiates Phase II Clinical Trial for HG146 in Adenoid Cystic Carcinoma
China-based HitGen Inc. (SHA: 688222) has announced the commencement of the first patient enrollment in...
Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion
Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...
Xtalpi Inc. Partners with NCCS and Duke-NUS to Advance AI-Driven Drug Discovery
Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...
Danaher Corporation Opens Joint Office in Beijing’s Chaoyang District
US-based Danaher Corporation (NYSE: DHR), a leading science and tech services provider, has officially launched...
WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Hainan Free Trade Port Gets Green Light for Temporary Import of Special Medical Foods
The State Administration for Market Regulation (SAMR) in China has given its approval in principle...
GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities
On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...
Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO
On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024,...
Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange
On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...